EMA Consults On Clinical Data Needed For Approving Hemophilia Non-Replacement Therapies
Executive Summary
With several non-replacement therapies in the pipeline for hemophilia patients, the European Medicines Agency explains how sponsors of these products should go about their phase III confirmatory trials.